(NYSE: VNRX) Is Our Top Watch Today. Here's Why:

VolitionRx is entering August with a string of potentially meaningful developments around its blood-based diagnostic technology. Most recently, on August 12, 2026, the company announced new evidence demonstrating the utility of its rapid, point-of-care finger-prick test in sepsis patients. The development builds on Volition's work to measure nucleosomes and NETosis without relying exclusively on centralized laboratory infrastructure. A finger-prick format could potentially move testing closer to emergency rooms, ICUs, physicians' offices and eventually other decentralized settings—an important development for a condition such as sepsis, where speed can be critical. The announcement comes just one week after Volition reported the first peer-reviewed publication covering its new Capture-Seq™ liquid-biopsy technology, giving investors multiple scientific catalysts to watch in a short period.

Volition is targeting a fundamental bottleneck in diagnostics: many serious diseases are difficult, expensive or invasive to detect and monitor, particularly at an early stage. Cancer diagnostics can involve imaging, biopsies and specialized molecular testing, while sepsis requires clinicians to identify deteriorating patients as quickly as possible. Volition's strategy is to use epigenetic changes in circulating nucleosomes to turn some of these diagnostic questions into simple blood tests. Its Nu.Q® portfolio spans cancer, NETosis/sepsis, veterinary oncology and pharmaceutical research, while its point-of-care work could ultimately reduce dependence on sophisticated centralized laboratories. Management estimates the Nu.Q® NETs opportunity alone at approximately $3.8 billion annually, while previously describing opportunities across its broader platforms totaling more than $27 billion.

VolitionRx is a multinational epigenetics company developing and commercializing blood-based tests designed to help detect and monitor diseases in humans and animals. Its technology focuses on nucleosomes—the DNA-protein structures that can carry measurable epigenetic information associated with disease. Its portfolio includes Nu.Q® NETs, Nu.Q® Cancer, Nu.Q® Vet, Nu.Q® Discover, and its newer Capture-Seq™ liquid-biopsy technology. Volition's research and development activities are centered in Belgium, with additional operations in the United States, London and Singapore. Its overarching goal is to make disease detection and monitoring simpler, less invasive and more accessible through routine blood testing.

What separates Volition from many early-stage diagnostics companies is the breadth of applications it is attempting to build from a common underlying epigenetics and nucleosome platform. Instead of relying on a single cancer indication, the company is pursuing human cancer, sepsis/NETosis, veterinary cancer, drug-development research and next-generation liquid biopsy opportunities. It is also increasingly pursuing an asset-light commercialization strategy through established diagnostics partners. The June Sysmex collaboration follows existing relationships involving companies including Werfen, Hologic and Antech, while management has reported discussions with numerous other global diagnostic and liquid-biopsy companies. If those relationships progress from evaluations into commercial licenses, Volition could potentially leverage partners' installed analyzer bases and sales infrastructure rather than having to build an equivalent global commercial organization itself. That combination of a versatile platform, relatively simple blood-test formats and partnership-driven commercialization is the core differentiator behind the VNRX story.

Disclaimer: Sponsored Content

Trader's Incentive is a subsidiary of Parabolic Equities LLC (the “Publisher”). The Publisher received Six Thousand USD in cash via wire transfer from Bullish Media LLC ("Bullish Media") for a one day campaign beginning and ending on August Twelfth Twenty Twenty Six, before the deduction of any applicable bank wire, PayPal, Wise, or electronic payment processing fees, in exchange for the publication and dissemination of the Information (as defined in the full disclaimer linked below). Bullish Media LLC, in turn, received funding acting on behalf of and with funding provided by the Issuer. All compensation received is strictly cash. Neither the Publisher nor Bullish Media LLC received any equity compensation, stock options, warrants, or securities-based consideration of any kind from the Issuer or any intermediary. Read the full disclaimer here: